The authors suggested that high TOP2A expression was associated with cancer cell resistance to chemotherapy.37 Some previous clinical studies reported that there was no significant association between TOP2A expression and clinical parameters in NSCLC patients.38 However, Hou et al reported high expression of TOP2A significantly increased risk of death in NSCLC patients, especially in lung adenocarcinoma patients. The gene discussed is TOP2A; the disease is lung adenocarcinoma.